Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
McKinsey
Accenture
Cerilliant
Moodys
Citi
Dow
Queensland Health
Boehringer Ingelheim
Chinese Patent Office

Generated: August 16, 2017

DrugPatentWatch Database Preview

Glaxosmithkline Con Company Profile

« Back to Dashboard

What is the competitive landscape for GLAXOSMITHKLINE CON, and what generic alternatives to GLAXOSMITHKLINE CON drugs are available?

GLAXOSMITHKLINE CON has twelve approved drugs.

There are twelve US patents protecting GLAXOSMITHKLINE CON drugs.

There are three hundred and twenty-four patent family members on GLAXOSMITHKLINE CON drugs in forty-eight countries.

Summary for Applicant: Glaxosmithkline Con

Patents:12
Tradenames:11
Ingredients:11
NDAs:12
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons
FLONASE SENSIMIST ALLERGY RELIEF
fluticasone furoate
SPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeYY ► Subscribe
Glaxosmithkline Cons
FLONASE SENSIMIST ALLERGY RELIEF
fluticasone furoate
SPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Cons
NICORETTE
nicotine polacrilex
TROCHE/LOZENGE;ORAL022360-001May 18, 2009OTCYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Cons
EXCEDRIN (MIGRAINE)
acetaminophen; aspirin; caffeine
TABLET;ORAL020802-001Jan 14, 1998OTCYesYes► Subscribe► Subscribe ► Subscribe
Glaxosmithkline Cons
FLONASE SENSIMIST ALLERGY RELIEF
fluticasone furoate
SPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Glaxosmithkline Con

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons
COMMIT
nicotine polacrilex
TROCHE/LOZENGE;ORAL021330-001Oct 31, 2002► Subscribe► Subscribe
Glaxosmithkline Cons
LAMISIL
terbinafine hydrochloride
SOLUTION;TOPICAL020749-001Oct 17, 1997► Subscribe► Subscribe
Glaxosmithkline Con
TRANSDERM SCOP
scopolamine
FILM, EXTENDED RELEASE;TRANSDERMAL017874-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Glaxosmithkline Cons
LAMISIL
terbinafine hydrochloride
SOLUTION;TOPICAL020749-001Oct 17, 1997► Subscribe► Subscribe
Glaxosmithkline Cons
COMMIT
nicotine polacrilex
TROCHE/LOZENGE;ORAL021330-002Oct 31, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GLAXOSMITHKLINE CON drugs

Drugname Dosage Strength Tradename Submissiondate
nicotine polacrilex
Gum2 mg
NICORETTE
1/22/2013
nicotine polacrilex
Gum4 mg
NICORETTE
1/22/2013
orlistat
Capsules60 mg
ALLI
9/8/2010

Non-Orange Book Patents for Glaxosmithkline Con

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,787,532 Formulation containing anti-inflammatory androstane derivatives► Subscribe
7,629,335Anti-inflammatory androstane derivative► Subscribe
6,537,983 Anti-inflammatory androstane derivatives► Subscribe
7,592,329Crystalline complexes of fluticasone-2-furoate► Subscribe
7,798,368Fluid dispensing device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Glaxosmithkline Con Drugs

Country Document Number Estimated Expiration
China1680425► Subscribe
Denmark1305329► Subscribe
China1671434► Subscribe
TaiwanI244486► Subscribe
Hong Kong1021313► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Glaxosmithkline Con Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
12/2008Austria► SubscribePRODUCT NAME: FLUTICASON FUROAT UND DESSEN SOLVATE
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C0042Belgium► SubscribePRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729
C0067France► SubscribePRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
429Luxembourg► Subscribe91429, EXPIRES: 20230111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Boehringer Ingelheim
Colorcon
Teva
Federal Trade Commission
QuintilesIMS
Medtronic
Baxter
Merck
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot